Jobs to be Done (JTBD)
for Manufacture of pharmaceuticals, medicinal chemical and botanical products (ISIC 2100)
The pharmaceutical industry is evolving from a product-centric model to a patient-centric, outcome-driven one. JTBD is highly relevant as it shifts focus from 'what drugs do' to 'what patients/HCPs hire drugs and related services for.' This is crucial for identifying unmet needs, justifying value...
Why This Strategy Applies
A methodology for understanding the functional, emotional, and social 'job' a customer is truly trying to get done, which leads to innovation opportunities.
GTIAS pillars this strategy draws on — and this industry's average score per pillar
These pillar scores reflect Manufacture of pharmaceuticals, medicinal chemical and botanical products's structural characteristics. Higher scores indicate greater complexity or risk — see the full scorecard for all 81 attributes.
What this industry needs to get done
When developing a new therapy for a complex disease, I want to accurately predict clinical trial success and market adoption for novel compounds, so I can allocate R&D resources effectively and bring truly impactful treatments to market faster.
High R&D costs and failure rates, exacerbated by `MD01 (4/5)` (market obsolescence risk), `MD04 (3/5)` (temporal synchronization constraints for trials), and `PM01 (4/5)` (unit ambiguity in early clinical signs), make accurate prediction a constant challenge.
- Clinical trial phase progression rate
- Time to market for successful compounds
- Percentage of R&D budget yielding commercialized products
When managing a global supply chain for active pharmaceutical ingredients (APIs) and finished products, I want to ensure continuous and compliant product availability, so I can meet patient demand and regulatory requirements without disruption.
Complex `MD02 (4/5)` (trade network interdependence) and `MD06 (4/5)` (distribution channel architecture) create significant challenges for supply chain resilience, especially with stringent `PM02 (5/5)` (logistical form factor) requirements for product stability and transport.
- On-time in-full (OTIF) delivery rate
- Supply chain disruption frequency
- Percentage of cold chain integrity maintained
When launching a new pharmaceutical product into a highly regulated and price-sensitive market, I want to clearly demonstrate the comprehensive value of my product beyond clinical efficacy, so I can secure favorable reimbursement and broad patient access.
`PM01 (4/5)` (unit ambiguity & conversion friction) makes it difficult to translate clinical outcomes into payer-relevant economic value, complicated by intense `MD03 (1/5)` (price pressure) and `MD08 (2/5)` (structural market saturation).
- Payer formulary inclusion rate
- Time to broad market access
- Real-world evidence (RWE) generation success rate
When ensuring all manufacturing and distribution processes adhere to evolving global regulatory standards, I want to maintain impeccable regulatory compliance and product quality, so I can avoid penalties, recalls, and reputational damage.
The sheer volume and dynamic nature of global regulations (`MD06: 4/5` distribution complexity, `MD05: 4/5` value-chain depth) make maintaining consistent compliance highly demanding, even with robust systems.
- Number of critical regulatory audit findings
- Product recall frequency
- Batch release success rate
When considering 'beyond-the-pill' solutions to complement core drug offerings, I want to identify and develop integrated solutions that address holistic patient and HCP needs, so I can differentiate my portfolio and capture new market segments.
Moving beyond traditional drug development requires new capabilities and a deeper understanding of diverse `MD05 (4/5)` (value-chain depth) stakeholders' unmet `PM01 (4/5)` (ambiguous) needs, often overcoming internal silos.
- Revenue from integrated solutions
- Patient adherence rates for integrated therapies
- Ecosystem partnership growth
When communicating product benefits and company values to the public and patient advocacy groups, I want to be perceived as a trustworthy and patient-centric innovator, so I can build public trust, foster positive patient relationships, and mitigate social activism risks.
Historical industry perceptions, high public expectations, and the sensitivity of health matters (`CS02: 1/5` heritage sensitivity) make earning and maintaining trust a continuous challenge, exacerbated by `CS03 (3/5)` social activism risks.
- Patient advocacy group collaboration index
- Net Promoter Score (NPS) from patient feedback programs
- Brand reputation score (media analysis)
When engaging with regulatory bodies and financial markets, I want to demonstrate robust governance, ethical conduct, and sustainable long-term value, so I can maintain my license to operate and attract investment capital.
Intense scrutiny over drug pricing (`MD03: 1/5`), ethical considerations (`CS04: 3/5`), and long R&D cycles (`MD04: 3/5`) demand transparent operations and consistent communication of long-term strategy, which requires substantial internal effort.
- ESG rating improvement
- Investor confidence index
- Debt-to-equity ratio stability
When making critical investment decisions in R&D or market expansion, I want to feel confident that my strategic choices will lead to successful outcomes and sustained growth, so I can justify significant resource allocation and navigate market challenges effectively.
The inherent uncertainty of drug development (`MD01: 4/5` market obsolescence risk), high investment stakes, and `MD08 (2/5)` (market saturation) create significant emotional pressure and risk aversion for leadership, despite advanced analytical tools.
- Strategic project success rate (go/no-go decisions)
- Leadership stress index (self-reported)
- Capital allocation efficiency
When contributing to the development and delivery of life-changing medicines, I want to feel a profound sense of purpose and pride in my work, so I can be motivated, engaged, and retained within the organization, enhancing productivity and innovation.
Bureaucracy, demanding regulatory environments, and the long timelines of drug development (`MD04: 3/5`) can sometimes obscure the direct impact of individual contributions, affecting `CS08 (3/5)` (workforce elasticity) and morale.
- Employee retention rate for R&D staff
- Employee engagement survey scores
- Internal recognition program participation
Strategic Overview
The Jobs to be Done (JTBD) framework offers a powerful lens for pharmaceutical and medicinal product manufacturers to innovate beyond traditional drug efficacy, focusing instead on the holistic 'job' patients, caregivers, and healthcare providers are trying to accomplish. In an industry facing 'Increasing Payer Scrutiny and Price Pressure' (MD03) and a constant need to differentiate in 'Structural Market Saturation' (MD08), understanding these underlying 'jobs' is critical for developing truly valuable and reimbursable solutions.
JTBD moves beyond mere product features to uncover the functional, emotional, and social dimensions of patient and HCP needs. For instance, a patient's 'job' might not just be 'take medication' but 'manage my chronic condition to live a full life' which involves adherence, side effect management, emotional support, and integration into daily routines. This deeper understanding can guide R&D to develop 'beyond-the-pill' solutions that address 'High Market Access Barriers' (MD06) and foster 'Market Access & Reimbursement for Novel Therapies' (MD08) by demonstrating superior holistic value.
By systematically applying JTBD, pharmaceutical companies can redefine their competitive landscape, identify 'Blue Ocean' opportunities (MD08), and develop integrated product-service offerings that resonate strongly with the evolving demands of patients and the healthcare system. This approach is instrumental in justifying premium pricing by clearly articulating the value created in helping various stakeholders 'get their jobs done' more effectively.
5 strategic insights for this industry
Patients' 'Jobs' Extend Beyond Drug Efficacy to Holistic Disease Management
A patient's 'job' is rarely just 'take this pill.' It encompasses managing symptoms, coping with side effects, maintaining quality of life, integrating treatment into daily routines, and managing emotional burden (CS01, CS06). Understanding these broader 'jobs' reveals opportunities for integrated solutions (e.g., drug + digital adherence tools, patient support programs).
Healthcare Providers (HCPs) 'Jobs' Involve Efficient, Effective, and Compliant Care Delivery
HCPs 'hire' pharmaceutical products not just for clinical outcomes but also to facilitate their 'jobs' of accurate diagnosis, streamlined treatment protocols, patient education, and regulatory compliance (MD06, PM01). Solutions that simplify HCP workflows, improve adherence, or offer better patient monitoring address critical 'jobs' for adoption.
Payers' 'Jobs' Focus on Value for Money and Population Health Outcomes
Payers 'hire' drugs that offer demonstrable value, reduce overall healthcare costs, and improve population health. Their 'job' is to balance innovation with affordability (MD03) and manage risk. Therefore, pharma companies must articulate how their products help payers achieve these 'jobs' through health economic outcomes research and real-world evidence.
'Beyond-the-Pill' Innovations Emerge from Unmet 'Jobs'
By deeply understanding unmet 'jobs,' pharmaceutical companies can identify innovation opportunities beyond traditional drug development, leading to the creation of digital therapeutics, connected devices, diagnostic tools, and integrated support services. These address areas of 'Structural Market Saturation' (MD08) by creating truly novel solutions.
JTBD Helps Redefine Competition and Unlock 'Blue Ocean' Markets
Applying JTBD allows companies to understand who or what their products truly compete against (e.g., lifestyle changes, other therapies, non-treatment) from the patient's perspective. This reframing helps 'Identifying and Capitalizing on 'Blue Ocean' Opportunities' (MD08) by creating products that uniquely 'get the job done' for segments currently underserved or overlooked.
Prioritized actions for this industry
Integrate JTBD methodology into early-stage R&D to define target product profiles based on deep patient and HCP needs.
By understanding the core 'jobs' from the outset, R&D can develop truly innovative products and integrated solutions that have higher clinical and commercial success rates, addressing 'High R&D Investment for New Products' and identifying 'Blue Ocean' opportunities.
Develop 'beyond-the-pill' integrated solutions (digital tools, support programs) that address the holistic 'jobs' of patients and caregivers.
These solutions enhance patient adherence, improve outcomes, and provide additional value beyond the drug itself, helping companies differentiate products amidst 'Increasing Payer Scrutiny' and 'Balancing Innovation with Affordability'. This also helps to extend product lifecycle beyond patent expiry.
Craft value propositions and generate real-world evidence (RWE) that explicitly demonstrate how products help payers achieve their 'jobs' of cost-effectiveness and population health outcomes.
Clearly articulating the value proposition in terms of payer 'jobs' is critical for securing favorable reimbursement and market access, directly addressing 'Increasing Payer Scrutiny and Price Pressure' and 'Market Access & Reimbursement for Novel Therapies'.
Establish cross-functional 'Job Teams' comprising R&D, Medical Affairs, Commercial, and Patient Advocacy to continuously identify and address 'jobs to be done'.
This collaborative approach ensures a comprehensive understanding of stakeholder 'jobs' across the product lifecycle, improving 'Market Access Barriers & Adoption Challenges' (CS01) and 'High Market Access Barriers' (MD06) by aligning development and commercialization efforts with true needs.
From quick wins to long-term transformation
- Conduct qualitative interviews and ethnographic studies with patients, caregivers, and HCPs for 1-2 key therapeutic areas to uncover critical 'jobs' and 'pain points'.
- Pilot a 'JTBD' workshop for a specific product team to re-evaluate their value proposition and identify potential 'beyond-the-pill' add-ons.
- Map current patient journeys to identify friction points where existing products fail to 'get the job done' completely.
- Incorporate JTBD insights into target product profile (TPP) development for new pipeline assets, ensuring products are designed to solve explicit 'jobs'.
- Develop and test prototypes of digital health solutions or patient support programs designed to address identified 'jobs' alongside existing medications.
- Refine clinical trial endpoints to include measures that reflect how well a product helps patients complete their 'jobs' (e.g., patient-reported outcomes).
- Embed JTBD as a core innovation principle across the entire organization, from discovery research to commercialization.
- Build strategic partnerships with technology companies or healthcare service providers to co-create and deliver integrated 'job-completing' solutions.
- Re-engineer business models to support value-based contracting, where reimbursement is tied to successfully helping patients 'get their job done' and achieve desired outcomes.
- Confusing 'jobs' with 'wants' or 'features,' leading to superficial innovations rather than addressing deep-seated needs.
- Failing to translate JTBD insights into actionable product development and commercial strategies.
- Lack of cross-functional alignment, resulting in siloed efforts that don't holistically address the 'jobs' of diverse stakeholders.
- Underestimating the investment required for 'beyond-the-pill' solutions and the associated regulatory and market access complexities.
Measuring strategic progress
| Metric | Description | Target Benchmark |
|---|---|---|
| Patient-Reported Outcome (PRO) Scores | Measures of how a treatment impacts a patient's quality of life, functional status, and ability to complete daily activities, directly reflecting 'job' completion. | Achieve statistically significant improvement in relevant PROs compared to standard of care or baseline. |
| Patient Adherence Rates | The percentage of patients who consistently follow their prescribed treatment regimen, indicating how well the 'job' of taking medication is supported. | >85% adherence rate for chronic conditions. |
| HCP Workflow Efficiency Improvement | Metrics such as time saved on patient education, reduced administrative burden, or improved diagnostic accuracy, indicating how well solutions support HCP 'jobs'. | Demonstrate >10% improvement in key HCP workflow efficiency metrics. |
| Value-Based Contracting Success Rate | The percentage of contracts with payers that are tied to outcomes, reflecting the ability to demonstrate value in achieving payer 'jobs'. | >30% of new market access agreements include value-based components. |
Software to support this strategy
These tools are recommended across the strategic actions above. Each has been matched based on the attributes and challenges relevant to Manufacture of pharmaceuticals, medicinal chemical and botanical products.
Capsule CRM
10,000+ customers worldwide • Includes Transpond marketing platform
Transpond's email marketing and audience tools support proactive brand communication that builds customer loyalty and reduces churn-driven reputational fragility
Cost-effective CRM for growing teams — manage contacts, track deals and pipeline, build customer relationships, and streamline day-to-day work. Paired with Transpond, a dedicated marketing platform for email campaigns and audience management.
Try Capsule FreeAffiliate link — we may earn a commission at no cost to you.
HubSpot
Free forever plan • 288,700+ customers in 135+ countries
Deal intelligence, win/loss analytics, and pipeline data give sales teams the evidence to defend price with ROI proof rather than discounting reactively against commodity competition
All-in-one CRM and go-to-market platform used by 288,700+ businesses across 135+ countries. Connects marketing, sales, service, content, and operations in one system — free forever plan to start, paid tiers to scale.
Try HubSpot FreeAffiliate link — we may earn a commission at no cost to you.
Other strategy analyses for Manufacture of pharmaceuticals, medicinal chemical and botanical products
Also see: Jobs to be Done (JTBD) Framework